EXEL

Exelixis
D

EXEL

44.345
USD
-0.03
(-0.06%)
مغلق
حجم التداول
123,870
الربح لكل سهم
2
العائد الربحي
-
P/E
19
حجم السوق
11,889,433,602
أصول ذات صلة الأخبار المقالات
المزيد

العنوان: Exelixis

القطاع: Healthcare
الصناعة: Biotechnology
Exelixis Inc is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.